Chemomab Therapeutics has announced that it has successfully completed its End-of-Phase 2 meeting with the FDA, aligning on the design of a single Phase 3 trial for its lead product candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback